The US investment bank says the phase 3 results in ovarian cancer change its view of the drug candidate and still point to ...

AbbVie will test lutikizumab together with ABBV-295, the amylin-based obesity drug it licensed from Danish biotech Gubra, ...

China has more house dust mite allergy sufferers than any other country, but fewer than 1 million of an estimated 100 million ...

All major hearing aid makers are launching new premium devices at the same time, but Søren Nielsen expects audiologists to ...

Former GN executive to lead Nordic expansion of AI cell-therapy company that took over Novo program Peter Aksel Villadsen leaves GN after six years to build up Cellular Intelligence in the Nordics, as ...

Xellia CEO warns EU: Critical antibiotics production is moving to China and India Michael Kocher sees only one realistic model for European supply security: a publicly owned plant that Xellia runs ...

ChemoMetec raises outlook after first quarter of fiscal 2026/27 The upward revision comes in response to increased demand, the company says.

Nordea raises Demant price target on strong US demand for Oticon Zeal Nordea sees signs of improvement in market growth in the US, and this could benefit the Danish hearing aid group Demant.

CSL agrees to pay up to USD 1.6bn for rights to Alentis’ rare kidney disease drug The Australian drugmaker will pay USD 355m upfront to the Novo Holdings-backed Swiss biotech to co-develop an ...

FDA delays decision on Novo's hemophilia drug Following the delayed decision, Novo now aims to launch the hemostatic agent denecimig in the US in the first half of 2027.

Novo study says Wegovy cut liver fat Liver fat fell to 3.1% from 8.8% over 72 weeks among 55 patients with obesity but not diabetes who took the drug.